NeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of “Hold” by Brokerages

NeuroPace, Inc. (NASDAQ:NPCEGet Rating) has been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $16.50.

A number of analysts recently weighed in on NPCE shares. Zacks Investment Research cut shares of NeuroPace from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 16th. Wells Fargo & Company decreased their price target on shares of NeuroPace from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Friday, March 11th. Wolfe Research started coverage on shares of NeuroPace in a research note on Tuesday, April 5th. They set an “outperform” rating and a $13.00 price target for the company. Morgan Stanley cut shares of NeuroPace from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $17.00 to $12.00 in a research note on Friday, January 7th. Finally, SVB Leerink decreased their price target on shares of NeuroPace from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, March 11th.

Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of NeuroPace in the 4th quarter worth $585,000. BlackRock Inc. lifted its stake in shares of NeuroPace by 1.8% in the fourth quarter. BlackRock Inc. now owns 340,087 shares of the company’s stock valued at $3,428,000 after purchasing an additional 6,113 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of NeuroPace in the fourth quarter valued at about $1,373,000. Revelation Capital Management LLC acquired a new stake in shares of NeuroPace in the fourth quarter valued at about $6,719,000. Finally, Soleus Capital Management L.P. lifted its stake in shares of NeuroPace by 38.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,309,003 shares of the company’s stock valued at $23,275,000 after purchasing an additional 638,867 shares during the period. Institutional investors own 49.85% of the company’s stock.

NASDAQ NPCE opened at $8.32 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 14.28 and a quick ratio of 13.44. The firm’s fifty day moving average price is $8.12 and its 200 day moving average price is $10.32. The company has a market capitalization of $203.60 million and a price-to-earnings ratio of -0.24. NeuroPace has a 12 month low of $6.75 and a 12 month high of $27.38.

NeuroPace (NASDAQ:NPCEGet Rating) last posted its earnings results on Thursday, March 10th. The company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.11). The company had revenue of $11.00 million during the quarter, compared to analysts’ expectations of $11.00 million. NeuroPace had a negative net margin of 79.85% and a negative return on equity of 141.26%. As a group, sell-side analysts forecast that NeuroPace will post -1.96 earnings per share for the current year.

NeuroPace Company Profile (Get Rating)

NeuroPace, Inc operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Further Reading

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.